Skip to main content
Sanofi's application for myeloma drug isatuximab accepted by FDA
7/11/2019

The FDA has accepted for review Sanofi's marketing application for the use of its monoclonal antibody therapy isatuximab as a treatment for patients with relapsed/refractory multiple myeloma. The agency set the action date for April 30, 2020.

Full Story: